ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
 PMID: 26578099       2015       Virology journal
Discussion: It is reported that a differential genetic barrier was found for V106M, V108I, P225H in different HIV-1 subtypes for NNRTI resistance-related substitutions.


  Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.
 PMID: 24444369       2014       AIDS research and therapy
Table: V108I


  Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.
 PMID: 24498008       2014       PloS one
Table: V108I


  Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.
 PMID: 24586665       2014       PloS one
Result: V108I accounted for 1.9%, and reduced NVP and EFV susceptibility.
Result: The mutations of both K103N and V108I caused high resistance to EFV and NVP.
Table: V108I


  Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
 PMID: 24633208       2014       The Journal of antimicrobial chemotherapy
Result: Individual mutations observed were G190AS (n = 8; 47%), Y181CV (n = 6; 35%), K101I (n = 3; 18%), A98G (n = 2; 12%), K103N (n = 2; 12%) and V108I (n = 1; 6%).


  A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
 PMID: 25259833       2014       AIDS (London, England)
Result: The next most common NNRTI-resistance mutations in subtype AFSU viruses were K103N (25 patients), Y181C (13 patients), G190A (8 patients), A98G (4 patients), V108I (3 patients), and Y188L (2 patients).


  Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.
 PMID: 25397500       2014       Journal of the International AIDS Society
Table: V108I


  HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.
 PMID: 25487529       2014       BMC research notes
Result: However four patients had diverse drug mutations combinations of K103N and V108IV (n = 1); Y184V, G190A and T215Y (n = 1); K103N, M184V and T215Y (n = 1); and A98G, Y181C (n = 1) mutations.
Result: These mutations were M184V (n = 1), T215Y (n = 2), V106A (n = 1), A98G (n = 1), Y18C1C (n = 1), G190A (n = 1) and V108IV (n = 1).


  Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
 PMID: 22842995       2013       AIDS (London, England)
Abstract: In patients with ETR failure, cross-resistance to RPV was seen in 27.6%, mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%).
Abstract: Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs.


  Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
 PMID: 23300238       2013       Clinical infectious diseases
Abstract: Four hundred twelve (98%) women had primary endpoint results available; of these, 5 (1.2%) had new NVP resistance detected by population genotype: 4 of 215 in the 7-day arms (1.9%; K103N in 4 women with Y181C, Y188C, or G190A in 3 of 4) and 1 of 197 (0.5%; V108I) in the 21-day arms (P = .37).



Browser Board

 Co-occurred Entities




   Filtrator